this piece corresponds to the legacy myPDB login in the form of a bootstrap modal, will likely retire-->

MFX

1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

MFX is found in 7 entries

MFX as free ligands, exist in 7 entries. Example includes: 5CDQ 2XKK 5BTA

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

Name1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Identifiers7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid
FormulaC21 H24 F N3 O4
Molecular Weight401.43 g/mol
TypeNON-POLYMER
Isomeric SMILESCOc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1
InChIInChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
InChIKeyFABPRXSRWADJSP-MEDUHNTESA-N

Chemical Details

Formal Charge0
Atom Count53
Chiral Atom Count2
Chiral AtomsC01,C02
Bond Count57
Aromatic Bond Count6
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00218 Different stereochemistry
NameMoxifloxacin
Groups
  • approved
  • investigational
DescriptionMoxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Synonyms1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
SaltsMoxifloxacin hydrochloride
Brand Names
  • Act Moxifloxacin
  • Apo-moxifloxacin
  • Auro-moxifloxacin
  • Avelox
  • Avelox Abc Pack
Affected OrganismEnteric bacteria and other eubacteria
IndicationFor the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
PharmacologyMoxifloxacin is a quinolone/fluoroquinolone antibiotic. Moxifloxacin can be used to treat infections caused by the following bacteria: Aerobic Gram-positive microorganisms: <i>Corynebacterium</i> species, <i>Micrococcus luteus</i>, <i>Staphylococcus aureus</i>, <i>Staphylococcus epidermidis</i>, <i>Staphylococcus haemolyticus</i>, <i>Staphylococcus hominis</i>, <i>Staphylococcus warneri</i>, <i>Streptococcus pneumoniae</i>, and <i>Streptococcus viridans</i> group. Aerobic Gram-negative microorganisms: <i>Acinetobacter lwoffii</i>, <i>Haemophilus influenzae</i>, and <i>Haemophilus parainfluenzae</i>. Other microorganisms: <i>Chlamydia trachomatis</i>.<br/>Moxifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.
Mechanism of actionThe bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
Route of administration
  • Intravenous
  • Ophthalmic
  • Oral
Categories
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antiinfectives
  • Antineoplastic Agents
  • Chemical Actions and Uses
ATC-Code
  • J01MA14
  • S01AE07
AHFS-Code
  • 08:12.18
  • 52:04.04
CAS number151096-09-2
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682